The Only Drug That Can Save These Babies Is Being Pulled Off Shelves
Pfizer just recalled lots of the only drug recommended to treat syphilis in pregnant women, compounding a shortage that's already lasted years. With congenital syphilis cases at historic highs, public health officials are calling it a preventable tragedy in slow motion.
A 100-Year-Old Drug, and Nothing Else Will Do
Penicillin was discovered in 1928. Almost a century later, it remains the only recommended treatment for syphilis in pregnant women. Not one of several options. Not the preferred choice among alternatives. The only one.
So when Pfizer announced a voluntary recall of specific lots of Bicillin L-A (the injectable penicillin used to treat syphilis), the public health world didn't just flinch. It panicked. Because this recall lands on top of a shortage that's already been grinding for years, at the exact moment the U.S. is experiencing a historic surge in syphilis among pregnant women and newborns.
This isn't a story about a drug recall. It's a story about what happens when the supply chain for an irreplaceable medicine snaps during an epidemic.
What Pfizer Actually Recalled
Pfizer pulled specific lots of Bicillin L-A, its penicillin G benzathine injectable suspension, after particulates were found during visual inspection. Tiny foreign particles, traced back to stoppers from an outside vendor, showed up in prefilled syringes.
The recall covers 12 lot numbers across both the 1.2 million-unit and 2.4 million-unit presentations. Pfizer's own health hazard assessment rated the risk to patients as "medium," and the company says it hasn't received any reports of adverse events tied to the affected lots.
On paper, that sounds manageable. In practice, it's gasoline on a fire that's been burning since 2023.
A Shortage That Won't Quit
Bicillin L-A has been on the FDA drug shortage list for years now. A critical shortage hit in spring 2023, forcing clinics across the country to ration shots. The situation dragged through 2024 with providers still scrambling. Then came the July 2025 recall, which pushed the estimated recovery timeline out even further.
As of mid-2026, Bicillin L-A remains on allocation, meaning Pfizer controls who gets it and how much. The current best estimate for full supply recovery? , with some state health departments warning it could stretch into 2027.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Late 2026 at the earliest
To patch the gap, the FDA has authorized temporary importation of Lentocilin, a benzathine penicillin G product manufactured overseas. Think of it like bringing in emergency rations during a famine: helpful, but not a permanent fix. And it doesn't change the underlying fragility of relying on essentially one manufacturer for a drug this critical.
Why This Matters More Than a Typical Drug Shortage
Most drug shortages are inconvenient. Doctors switch to an alternative. Patients deal with a slightly different formulation. Life goes on.
Syphilis in pregnancy is different. The CDC's treatment guidelines couldn't be clearer: "Parenteral penicillin G is the only therapy with documented efficacy for syphilis during pregnancy." If a pregnant patient is allergic to penicillin, the recommendation isn't to use something else. It's to desensitize them to penicillin and then give them penicillin anyway.
Doxycycline, the main alternative for non-pregnant adults, is classified as FDA Pregnancy Category D. Translation: it can harm the developing baby. Ceftriaxone? Not proven to prevent transmission to the fetus. There is, quite literally, no Plan B for pregnant patients.
That makes this recall feel less like a supply chain hiccup and more like someone pulling the only fire extinguisher out of a burning building.
The Numbers Behind the Crisis
The timing could hardly be worse. Maternal syphilis (syphilis diagnosed during pregnancy) has been climbing at an alarming pace. From 2016 to 2022, the maternal syphilis rate jumped 222%. Then from 2022 to 2024, it climbed another 28%, reaching 357.9 cases per 100,000 births.
The disparities are staggering. Among American Indian and Alaska Native women, the rate surged 52% in just two years. Among Black women, it rose 30%. These aren't abstract numbers; they represent real pregnancies where timely treatment could mean the difference between a healthy baby and a devastating outcome.
Congenital syphilis (the disease passed from mother to child before or during birth) hit nearly 4,000 cases in 2024. That's the 12th consecutive year of increases, and roughly 700% higher than 2015 levels. The rate of growth has slowed recently, with cases rising only about 2-3% from 2023 to 2024 compared with double-digit annual jumps in prior years. But the absolute numbers remain at historic highs.
And here's the gut punch: congenital syphilis is almost entirely preventable. Screen pregnant women early. Treat them with penicillin. That's it. Studies suggest timely treatment is about 98% effective at preventing transmission. The problem isn't medical knowledge. It's access to the drug.
Triage Mode
Public health agencies are now operating in full triage mode. The CDC's directive is blunt: reserve all available Bicillin L-A for pregnant patients and infants with congenital syphilis. Everyone else gets doxycycline (14 days for early syphilis, 28 days for late or unknown duration).
State health departments from Massachusetts to California to Maine have issued similar advisories. When local supply runs out, clinicians are directed to contact their state's STD program or use Pfizer's Medical Request Process, which is restricted to cases involving congenital syphilis or pregnancy.
But that process has drawn sharp criticism. The National Coalition of STD Directors has called it slow and administratively burdensome, describing documented cases where paperwork delays meant a pregnant patient delivered before treatment could be arranged. When you're racing against a biological clock (ideally, treatment should happen at least 30 days before delivery), every day of bureaucratic delay carries real consequences.
A Deeper Problem Than One Recall
Infectious disease experts have been blunt in their assessments. The situation has been described as "really a tragedy, because it's totally preventable." The combination of rising syphilis rates, constrained drug supply, and complex access pathways creates what officials are calling a "perfect storm" for worsened outcomes.
But the deeper issue goes beyond Pfizer or any single recall. The U.S. has essentially concentrated manufacturing of a critical, irreplaceable antibiotic in the hands of one primary supplier. There's no robust stockpile. No redundant manufacturing capacity. No contingency plan that doesn't involve emergency imports from overseas.
Public health leaders are now pushing for stronger federal stewardship of critical drug supplies, investment in domestic manufacturing of benzathine penicillin G, and better coordination between Pfizer, the FDA, the CDC, and local health systems.
What Comes Next
The optimistic scenario: Pfizer resolves its manufacturing issues, Lentocilin imports bridge the gap, and supply normalizes by late 2026 or early 2027. The broader syphilis epidemic, which showed some signs of slowing in 2024 (primary and secondary cases fell about 22% from 2023 to 2024), continues to bend downward.
The pessimistic scenario: supply recovery drags into 2027, maternal syphilis rates keep climbing, and the congenital syphilis numbers that had just started to plateau tick back up because pregnant women simply can't get the one drug they need.
A century after Alexander Fleming's famous accident, we're watching the world's most essential antibiotic become the world's hardest to find, at the worst possible time. Penicillin can prevent congenital syphilis almost every time it's given. The question isn't whether the drug works. It's whether we can get it to the people who need it.
4 min read
Sanofi Just Killed Its Own Heir to the Throne
Sanofi axed amlitelimab, the $1.1B next-generation eczema drug that was supposed to succeed its $11.6B blockbuster Dupixent. The problem? It wasn't actually better. Now Sanofi's post-Dupixent immunology strategy has a gaping hole and a ticking patent clock.
